Lupin recalls diabetes treatment drug 'Metformin' in US mark
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Mumbai-based drugmaker Lupin Pharmaceuticals is voluntarily recalling a variant of its anti-diabetic medicine metformin hydrochloride in the US market due to the presence of a cancer-causing substance.

US Food and Drug Administration (FDA) announced the recall and said its analysis revealed that One lot (G901203) of the extended-release tablets of 500 mg “exceeded the acceptable daily intake limit for the impurity N-Nitrosodimethylamine (NDMA).”

On 28 May, the US FDA had announced that the agency laboratory testing had revealed levels of NDMA above the agency’s acceptable intake limit in several lots of the extended-release (ER) formulation of metformin.

• Impact on Indian Market:

“In view of carcinogenic impurities in long-acting (ER) metformin preparation, we have stopped prescribing this drug,” said Dr Anoop Misra, chairman of the Delhi-based Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. “On the other hand, we will continue to use plain metformin since it is the best drug for diabetes,” he said.

The Indian drug regulator, Central Drug Standard Control Organisation (CDSCO) said, “while we haven’t noticed any concerns with the Indian products, we are monitoring the US FDA updates closely."

Source: https://theprint.in/health/indian-drugmaker-lupin-to-voluntarily-recall-metformin-variant-a-diabetes-drug-in-us/440241/
Dr. I●●●●●●E G●●●A and 1 others like this4 shares
Like
Comment
Share